Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

作者：David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie Thompson, Cynthia Brinson, Debbie Hagins, Moti Ramgopal, Andrea Antinori, Xuelian Wei, Rima Acosta, Sean E Collins, Diana M. Brainard, Hal Martin · 发表于：The Lancet HIV · 年份：2019 · DOI：10.1016/s2352-3018(19)30077-3 · 被引用次数：167 · 研究领域：HIV/AIDS drug development and treatment、Hepatitis B Virus Studies、HIV/AIDS Research and Interventions